These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24790357)

  • 21. Calcium-sensing receptor sequencing in 21 patients with idiopathic or familial parathyroid disorder: pitfalls and characterization of a novel I32 V loss-of-function mutation.
    Szalat A; Shahar M; Shpitzen S; Nachmias B; Munter G; Gillis D; Durst R; Mevorach D; Leitersdorf E; Meiner V; Rosen H
    Endocrine; 2015 Mar; 48(2):444-53. PubMed ID: 25091521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification and characterization of D410E, a novel mutation in the loop 3 domain of CASR, in autosomal dominant hypocalcemia and a therapeutic approach using a novel calcilytic, AXT914.
    Park SY; Mun HC; Eom YS; Baek HL; Jung TS; Kim CH; Hong S; Lee S
    Clin Endocrinol (Oxf); 2013 May; 78(5):687-93. PubMed ID: 23009664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autosomal dominant hypocalcemia caused by an activating mutation of the calcium-sensing receptor gene: the first case report in Korea.
    Kim MY; Tan AH; Ki CS; Lee JI; Jang HW; Shin HW; Kim SW; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    J Korean Med Sci; 2010 Feb; 25(2):317-20. PubMed ID: 20119591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Checkpoint Inhibitor-Induced Hypoparathyroidism Associated With Calcium-Sensing Receptor-Activating Autoantibodies.
    Piranavan P; Li Y; Brown E; Kemp EH; Trivedi N
    J Clin Endocrinol Metab; 2019 Feb; 104(2):550-556. PubMed ID: 30252069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of pathogenic calcium sensing receptor mutations in sporadic idiopathic hypoparathyroidism.
    Sarin R; Tomar N; Ray D; Gupta N; Sharma YD; Goswami R
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):359-63. PubMed ID: 16918956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amino alcohol- (NPS-2143) and quinazolinone-derived calcilytics (ATF936 and AXT914) differentially mitigate excessive signalling of calcium-sensing receptor mutants causing Bartter syndrome Type 5 and autosomal dominant hypocalcemia.
    Letz S; Haag C; Schulze E; Frank-Raue K; Raue F; Hofner B; Mayr B; Schöfl C
    PLoS One; 2014; 9(12):e115178. PubMed ID: 25506941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autosomal dominant hypoparathyroidism with severe hypomagnesemia and hypocalcemia, successfully treated with recombinant PTH and continuous subcutaneous magnesium infusion.
    Sanda S; Schlingmann KP; Newfield RS
    J Pediatr Endocrinol Metab; 2008 Apr; 21(4):385-91. PubMed ID: 18556971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diseases associated with calcium-sensing receptor.
    Vahe C; Benomar K; Espiard S; Coppin L; Jannin A; Odou MF; Vantyghem MC
    Orphanet J Rare Dis; 2017 Jan; 12(1):19. PubMed ID: 28122587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glial cells missing-2 (GCM2) transactivates the calcium-sensing receptor gene: effect of a dominant-negative GCM2 mutant associated with autosomal dominant hypoparathyroidism.
    Canaff L; Zhou X; Mosesova I; Cole DE; Hendy GN
    Hum Mutat; 2009 Jan; 30(1):85-92. PubMed ID: 18712808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impaired growth and intracranial calcifications in autosomal dominant hypocalcemia caused by a GNA11 mutation.
    Tenhola S; Voutilainen R; Reyes M; Toiviainen-Salo S; Jüppner H; Mäkitie O
    Eur J Endocrinol; 2016 Sep; 175(3):211-8. PubMed ID: 27334330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation.
    Theman TA; Collins MT; Dempster DW; Zhou H; Reynolds JC; Brahim JS; Roschger P; Klaushofer K; Winer KK
    J Bone Miner Res; 2009 May; 24(5):964-73. PubMed ID: 19063686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
    Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
    Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel mutation in the calcium-sensing receptor responsible for autosomal dominant hypocalcemia in a family with two uncommon parathyroid hormone polymorphisms.
    Alvarez-Hernández D; Santamaría I; Rodríguez-García M; Iglesias P; Delgado-Lillo R; Cannata-Andía JB
    J Mol Endocrinol; 2003 Oct; 31(2):255-62. PubMed ID: 14519094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An interesting case of primary hypoparathyroidism.
    Kirpalani DA; Patel J; Shah H; Kirpalani A; Amrapurkar D; Choudhary R; Dhurve A
    Indian J Nephrol; 2014 May; 24(3):175-7. PubMed ID: 25120296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel gain of function mutations of the calcium-sensing receptor in two patients with PTH-deficient hypocalcemia.
    Nakajima K; Yamazaki K; Kimura H; Takano K; Miyoshi H; Sato K
    Intern Med; 2009; 48(22):1951-6. PubMed ID: 19915295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Homozygous Calcium-Sensing Receptor Polymorphism R544Q Presents as Hypocalcemic Hypoparathyroidism.
    Cavaco BM; Canaff L; Nolin-Lapalme A; Vieira M; Silva TN; Saramago A; Domingues R; Rutter MM; Hudon J; Gleason JL; Leite V; Hendy GN
    J Clin Endocrinol Metab; 2018 Aug; 103(8):2879-2888. PubMed ID: 29846619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neonatal Hypocalcemic Seizures in Offspring of a Mother With Familial Hypocalciuric Hypercalcemia Type 1 (FHH1).
    Dharmaraj P; Gorvin CM; Soni A; Nelhans ND; Olesen MK; Boon H; Cranston T; Thakker RV; Hannan FM
    J Clin Endocrinol Metab; 2020 May; 105(5):1393-400. PubMed ID: 32150253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CASRdb: calcium-sensing receptor locus-specific database for mutations causing familial (benign) hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia.
    Pidasheva S; D'Souza-Li L; Canaff L; Cole DE; Hendy GN
    Hum Mutat; 2004 Aug; 24(2):107-11. PubMed ID: 15241791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1).
    Hannan FM; Walls GV; Babinsky VN; Nesbit MA; Kallay E; Hough TA; Fraser WD; Cox RD; Hu J; Spiegel AM; Thakker RV
    Endocrinology; 2015 Sep; 156(9):3114-21. PubMed ID: 26052899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subcutaneous Infusion of rhPTH
    Shulman D
    J Endocr Soc; 2022 May; 6(5):bvac031. PubMed ID: 35350394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.